(difelikefalin)
See how daily doses of Veltassa (patiromer) as a monotherapy
provide reliable potassium control to patients in a new cohort
study of hyperkalaemia in the acute care setting
 |
Veltassa is indicated for the treatment of hyperkalaemia in adults.1 |
Seize control of your patients’ K+ levels with Veltassa in the acute setting
Veltassa should not replace emergency treatment for life-threatening hyperkalaemia1
RELIABLE POTASSIUM CONTROL
- Reduces K+ levels from the first dose, regardless of hyperkalaemia severity2
- Serum K+ reduction in 4 hours, significant reduction at 7 hours (p=0.004) from baseline after first dose3
PATIENT CONVENIENCE
- The only K+ binder with once-daily dosing from the start1
- Suitable for patients who cannot tolerate even a small increase in sodium1,4
Real-world data in over 800 patients shows that Veltassa significantly reduced serum K+ from baseline2
The outcomes associated with Veltassa as a monotherapy in patients with hyperkalaemia in an acute care setting were evaluated in a real-world retrospective cohort study (N=881) using electronic health record data.
Study designABSOLUTE sK+ LEVEL REDUCTION
ACROSS ALL TIME INTERVALS
Adapted from Di Palo K E et al, 20222
*In the 24 hours after the initial administration of Veltassa, 725 (82.3%) patients received no further doses of K+ binders, 137 (15.5%) patients received one additional dose and 19 (2.2%) patients received two or more additional doses.2
In the study, initially, 81.8% (n=721) of patients received 8.4 g of Veltassa daily; 17.5% (n=154) of patients received 16.8 g daily; 0.7% (n=6) of patients received 25.2 g daily.2 Veltassa is indicated for the treatment of hyperkalaemia in adults. The recommended starting dose is 8.4 g Veltassa once daily up to a maximum dose of 25.2 g daily.1 Please always refer to the Veltassa Summary of Product Characteristics for full prescribing details.
Veltassa is generally well tolerated in clinical trials1
The most common (≥1/100 to <1/10) adverse reactions observed in clinical studies were mostly mild-to-moderate and generally resolved spontaneously or with treatment:1
| Constipation | Hypomagnesaemia* | Diarrhoea | Abdominal pain | Flatulence |
|---|---|---|---|---|
| 6.2% | 5.3% | 3.0% | 2.9% | 1.8% |
| Constipation | 6.2% |
|---|---|
| Hypomagnesaemia* | 5.3% |
| Diarrhoea | 3.0% |
| Abdominal pain | 2.9% |
| Flatulence | 1.8% |
Uncommon adverse reactions (≥1/1,000 to <1/100) included nausea and/or vomiting.1
†Hypomagnesaemia was mild-to-moderate, with no patient developing a serum magnesium level <1 mg/dL (0.4 mmol/L). Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels.1
Read a patient case study to learn more about Veltassa for patients with acute hyperkalaemia
Veltassa is indicated for the treatment of hyperkalaemia in adults1
Enables RAASi therapy5-7
The only K+ binder with once-daily dosing from the start1
Specifically designed to exchange K+ for Ca1,4
Suitable for ongoing prescribing in primary care.8‡
‡Initiation must be in specialist care.8
RAASi, renin-angiotensin-aldosterone system inhibitor.
Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: medicalInfo_UK@viforpharma.com
Study design:2
This retrospective cohort study used electronic health record data from adult patients treated with Veltassa® (patiromer) for acute hyperkalaemia in emergency departments, inpatient units and intensive care units at an academic medical centre in New York. Data recorded between 30 January 2018 and 30 December 2019 that contained at least one prescription of Veltassa, were eligible for inclusion in the study.
881 patients who were aged 18 years or older with acute, non-life-threatening hyperkalaemia and treated with a single dose (8.4 g, 16.8 g or 25.2 g) of Veltassa were included.
In the study, initially, 81.8% (n=721) of patients received 8.4 g of Veltassa daily; 17.5% (n=154) of patients received 16.8 g daily; 0.7% (n=6) of patients received 25.2 g daily.2 Veltassa is indicated for the treatment of hyperkalaemia in adults. The recommended starting dose is 8.4 g Veltassa once daily up to a maximum dose of 25.2 g daily.1 Please always refer to the Veltassa Summary of Product Characteristics for full prescribing details.
| Primary outcome (met) | The mean absolute reduction in serum K+ level from baseline at 3 time periods after the administration of Veltassa: 0-6 hours, >6-12 hours and >12-24 hours |
| Secondary outcomes |
|
The incidence of hypokalaemia and hypomagnesaemia
At 24 hours after Veltassa administration, the incidence of hypokalaemia was low; two patients experienced mild, asymptomatic hypokalaemia (defined as serum potassium level <3.5 mEq/L) with serum potassium concentrations between 3.2 mEq/L and 3.4 mEq/L. 68 patients experienced hypomagnesaemia (defined as serum magnesium level <1.7 mg/dL) at 24 hours after Veltassa administration, similar to the incidence reported in clinical trials.2
Prescribing information and adverse event reporting
References
1. Veltassa Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2023.
2. Di Palo K E et al. JAMA Netw Open 2022;5:e2145236.
References
1. Veltassa Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed November 2022. 2. Di Palo K E, Sinnett M J, Goriacko P. Assessment of patiromer monotherapy for hyperkalemia in an acute care setting. JAMA Netw Open 2022;5(1):e2145236 ( +suppl). 3. Bushinsky D A, Williams G H et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015;88(6):1427-1433. 4. Li L, Harrison S D et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 2016;21(5):456-465. 5. Weir M R, Bakris G L et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372(3):211-221 (suppl). 6. Pitt B, Anker S D et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32(7):820-828. 7. Agarwal R, Rossignol P et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394(10208):1540-1550. 8. National Institute for Health and Care Excellence (NICE). NICE technology appraisal guidance 623. Patiromer for treating hyperkalaemia, February 2020. Available at: www.nice.org.uk. Accessed November 2022.
More about Veltassa
Veltassa tolerability
Veltassa and RAASi
Welcome to
Help us guide you to the right place:
I am a UK healthcare
professional or UK healthcare
decision maker
This is me, continue 
I am not a UK healthcare
professional or UK healthcare
decision maker
This is me, continue